Yolanda Clay Po
Internal Medicine · Austin, TXNPI 1164405833
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,800 of the $7,065 with a category attached, or 82.1%. It is spread thinly across 28 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,480 and has fallen 79.3% since, to $514 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- GSK$887
- Novo Nordisk$771
- Boehringer Ingelheim$740
- AstraZeneca$686
- Lilly USA, LLC$400
- plus $2K from 22 others
Across 5 payments — averaging $6650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$33K
What the payments were for
- Consulting fees$1,20017%
- Food & beverage$5,80082%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,274 |
| GSK | 39 | $887 |
| Novo Nordisk | 45 | $771 |
| Boehringer Ingelheim | 43 | $740 |
| AstraZeneca | 29 | $686 |
| Lilly USA, LLC | 22 | $400 |
| Amarin Pharma, Inc. | 13 | $367 |
| Pfizer | 17 | $310 |
| AbbVie(2 entities) | 20 | $298 |
| Astellas Pharma US Inc | 11 | $286 |
| Merck | 14 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $166 |
| Eisai Inc. | 5 | $88 |
| Exact Sciences | 4 | $84 |
| Avvisto Therapeutics, LLC | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Althera Pharmaceuticals LLC | 3 | $46 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Johnson & Johnson | 3 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Dexcom, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Amgen | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- FARXIGA$235
- Vascepa$129
- SHINGRIX$114
How this compares
$7,065 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $24,226 |
| OzempicSemaglutide | 15 | $20,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,017 |
| Losartan Potassium | 35 | $462 |
| Atorvastatin Calcium | 47 | $426 |
| Duloxetine Hcl | 11 | $394 |
| Omeprazole | 28 | $328 |
| Fluticasone Propionate | 16 | $278 |
| Lisinopril | 19 | $170 |
| Metformin Hcl | 29 | $160 |
| Hydrochlorothiazide | 15 | $158 |
| Levothyroxine Sodium | 22 | $155 |
| Spironolactone | 19 | $147 |
| Sertraline Hcl | 25 | $136 |
| Gabapentin | 17 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $400 | $24,22620 claims |
| Novo NordiskOzempic | $771 | $20,50215 claims |
| GSKTrelegy Ellipta | $887 | $12,01713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Austin
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.